Lack of correlation between blood group and HER‑2 status in adenocarcinomas of the upper gastrointestinal tract

Hejna,Michael; Birner,Peter; Preusser,Matthias; Thallinger,Christiane  M. R.; Worel,Nina; Asari,Reza; Dolak,Werner; Schmid,Rainer; Schoppmann,Sebastian  F.; Raderer,Markus

doi:10.3892/mco.2013.181

Lack of correlation between blood group and HER‑2 status in adenocarcinomas of the upper gastrointestinal tract

Authors:
- Michael Hejna
- Peter Birner
- Matthias Preusser
- Christiane M. R. Thallinger
- Nina Worel
- Reza Asari
- Werner Dolak
- Rainer Schmid
- Sebastian F. Schoppmann
- Markus Raderer
View Affiliations

Affiliations: Department of Internal Medicine I, Medical University of Vienna, A‑1090 Vienna, Austria, Department of Pathology, Medical University of Vienna, A‑1090 Vienna, Austria, Department of Blood Group Serology/Transfusion Medicine, Medical University of Vienna, A‑1090 Vienna, Austria, Department of Surgery, Medical University of Vienna, A‑1090 Vienna, Austria, Department of Internal Medicine III, Medical University of Vienna, A‑1090 Vienna, Austria, Department of Radiotherapy, Medical University of Vienna, A‑1090 Vienna, Austria
Published online on: September 12, 2013 https://doi.org/10.3892/mco.2013.181
Pages: 1079-1083

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The assessment of the human epidermal growth factor receptor‑2 (HER‑2) status has become a routine diagnostic procedure for patients with advanced‑stage gastroesophageal adenocarcinoma. The aim of this study was to evaluate the possible correlation between the HER‑2 status and the ABO blood group. HER‑2 status determination and routine ABO typing was performed according to current standards. We evaluated the correlation between the HER‑2 status and the ABO and Rhesus (Rh) system in 100 consecutive patients with adenocarcinoma of the upper gastrointestinal tract. There were no significant differences between HER‑2 status and ABO and Rh system. Furthermore, no correlation was observed between the HER‑2 status and the ABO and Rh type in patients with adenocarcinoma of the upper gastrointestinal tract.

View Figures

View References

1.	Landsteiner K: Zur Kenntnis der antifermentativen, lytischen und agglutinierenden Wirkungen des Blutserums und der Lymphe. Zentralbl Bakteriol. 27:357–362. 1900.(In German).
2.	Bang YJ, Van Cutsem E, Feyereislova A, et al ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar
3.	Bang Y, Chung H, Sawaki A, Xu J, Shen L, Lipatov O, Park SR, Gangadharan VP, Advani SH and Kang YK: HER-2-positivity rates in advanced gastric cancer (GC): Results from a large international phase III trial. J Clin Oncol. 26(Suppl)4526:2008
4.	Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Al-Sakaff N, Lipatov O, See C, Rueschoff J and Van Cutsem E: Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol. 27(Suppl)4556:2009
5.	Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M and Birner P: Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol. 34:1868–1873. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Aird I, Bentall HH and Roberts JA: A relationship between cancer of stomach and the ABO blood groups. Br Med J. 1:799–801. 1953. View Article : Google Scholar : PubMed/NCBI
7.	Edgren G, Hjalgrim H, Rostgaard K, Norda R, Wikman A, Melbye M and Nyren O: Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol. 172:1280–1285. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J and Henkel T: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Fridey J: Standards for Blood Banks and Transfusion Services. 22nd edition. American Association of Blood Banks; Bethesda, MD: 2002
10.	Siewert JR and Stein HJ: Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 85:1457–1459. 1998. View Article : Google Scholar : PubMed/NCBI
11.	Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965.
12.	Lee JS, Ro JY, Sahin AA, Hong WK, Brown BW, Mountain CF and Hittelman WN: Expression of blood-group antigen A - a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med. 324:1084–1090. 1991. View Article : Google Scholar : PubMed/NCBI
13.	Gates MA, Wolpin BM, Cramer DW, Hankinson SE and Tworoger SS: ABO blood group and incidence of epithelial ovarian cancer. Int J Cancer. 128:482–486. 2011. View Article : Google Scholar : PubMed/NCBI
14.	Dabelsteen E and Gao S: ABO blood-group antigens in oral cancer. J Dent Res. 84:21–28. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Wolpin BM, Chan AT, Hartge P, Chanock SJ, Kraft P, Hunter DJ, Giovannucci EL and Fuchs CS: ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 101:424–431. 2009. View Article : Google Scholar : PubMed/NCBI
16.	Lennon AM, Klein AP and Goggins M: ABO blood group and other genetic variants associated with pancreatic cancer. Genome Med. 2:392010. View Article : Google Scholar : PubMed/NCBI
17.	Ürün Y, Utkan G, Yalcin Ş, et al: Lack of any relationship between ABO and Rh blood groups and clinicopathological features in patients with gastrointestinal stromal tumors: Turkish Oncology Group. Asian Pac J Cancer Prev. 13:4129–4131. 2012.PubMed/NCBI
18.	Costantini M, Fassio T, Canobbio L, Landucci M, Resasco M and Boccardo F: Role of blood groups as prognostic factors in primary breast cancer. Oncology. 47:308–312. 1990. View Article : Google Scholar : PubMed/NCBI
19.	Aird I, Bentall HH, Mehigan JA and Roberts JA: The blood groups in relation to peptic ulceration and carcinoma of colon, rectum, breast, and bronchus; an association between the ABO groups and peptic ulceration. Br Med J. 2:315–321. 1954. View Article : Google Scholar : PubMed/NCBI
20.	Goldenberg IS and Hayes MA: Breast carcinoma and ABO blood groups. Cancer. 11:973–974. 1958. View Article : Google Scholar : PubMed/NCBI
21.	Dede DS, Aksoy S, Dizdar O, Cerci P, Gullo I, Ozisik Y and Altundag K: Blood ABO groups and risk of breast cancer. Med Oncol. 27:14332010. View Article : Google Scholar : PubMed/NCBI
22.	Stamatakos M, Kontzoglou K, Safioleas P, Safioleas C, Manti C and Safioleas M: Breast cancer incidence in Greek women in relation to ABO blood groups and Rh factor. Int Semin Surg Oncol. 6:142009. View Article : Google Scholar : PubMed/NCBI
23.	Urun Y, Koru-Sengul T, Altundag K, Utkan G, Onur H, Akbulut H, Demirkazik A and Icli F: ABO blood group and the risk of breast cancer: Multicenter, case-control, observational study. J Clin Oncol. 30(Suppl)1572:2012
24.	Ürün Y, Utkan G, Altundag K, et al: ABO and Rh blood groups frequency in women with HER2 positive breast cancer. J BUON. 17:457–460. 2012.PubMed/NCBI
25.	Klimant E, Glurich I, Mukesh B and Onitilo AA: Blood type, hormone receptor status, HER2/neu status, and survival in breast cancer: a retrospective study exploring relationships in a pheno-typically well-defined cohort. Clin Med Res. 9:111–118. 2011. View Article : Google Scholar : PubMed/NCBI
26.	Austrian Red Cross: Blood Groups. https://www.roteskreuz.at/home/. Accessed July 19, 2012.